select trial semaglutide cardiovascular outcomes non-diabetic 2023 and by baseline and changes in adiposity measurements: a prespecified analysis of the Semaglutide and Cardiovascular Outcomes in

This review explores the complex interplay between hyperkalemia and the use of guideline-directed medical therapies (GDMT), such as reninangiotensinaldosterone system inhibitors (RAASi) and steroidal mineralocorticoid receptor antagonists (sMRAs), including spironolactone and eplerenone, which are currently recommended in guidelines for improving outcomes in heart failure with reduced ejection fraction (HFrEF)

GLP-1 Orforglipron a low-molecular-weight oral GLP-1 receptor agonist

Expert guidance on safety, managing side effects, & preventing post-surgery diarrhoea.

Book an appointment with us today!

Purity: 99% (HPLC Certified) Form: Lyophilized powder

Unfortunately, being overweight is linked to a long list of health issues